The Primary Oral Insulin Trial (POInT) investigates whether type 1 diabetes in at-risk children can be prevented through oral insulin treatment. First results mark an important step toward the prevention of type 1 diabetes, pointing future efforts to personalized strategies. The group led by researchers from Helmholtz Munich and the Technical University of Munich (TUM) found that oral insulin treatment affects subgroups differently depending on their insulin gene variant.
This article was originally published on MedicalXpress.com
